SCHEMBL12204615

SCHEMBL12204615

O=C(N/C=C/c1cccs1)Nc1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.62
▸ KMT2A Q03164 9/20 0.62
▸ MAPT P10636 8/20 0.62
▸ NPC1 O15118 7/20 0.62
▸ LMNA P02545 7/20 0.62
▸ ALDH1A1 P00352 7/20 0.62
▸ RAB9A P51151 7/20 0.62
▸ SMN1; SMN2 Q16637 6/20 0.62
▸ KDM4E B2RXH2 1/20 0.62
▸ CYP3A4 P08684 1/20 0.56
▸ HTT P42858 4/20 0.51
▸ TSHR P16473 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ SENP8 Q96LD8 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913015 0.87 RAB9A (0.56) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL4913013 0.87 RAB9A (0.56) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL17664304 0.83 MAPT (0.48) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL4921577 0.80 MEN1 (0.58) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL4921584 0.80 MEN1 (0.58) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL15965551 0.78 LMNA (0.53) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL29518023 0.78 HTT (0.51) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL17664295 0.76 NPC1 (0.60) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL17664291 0.75 MAPT (0.62) MEN1KMT2AMAPTNPC1LMNA
SCHEMBL19435724 0.72 HCAR2 (0.53) MEN1KMT2AMAPTNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 — — US disclosed
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 — — US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 — — US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 MEN1 2102/4885KMT2A 4330/4885MAPT 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback